BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

BCR-ABL1 mutations are a common, well-characterized mechanism of resistance to imatinib as first-line treatment of chronic myeloid leukemia in chronic phase (CML-CP). Less is known about mutation development during first-line treatment with dasatinib and nilotinib, despite increased use because of h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Leukemia
Autors principals: Hughes, T P, Saglio, G, Quintás-Cardama, A, Mauro, M J, Kim, D-W, Lipton, J H, Bradley-Garelik, M B, Ukropec, J, Hochhaus, A
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4559757/
https://ncbi.nlm.nih.gov/pubmed/26118315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.168
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars